Residency · Residency · Psychiatry

Alcohol Withdrawal and Delirium Tremens

Pathophysiology of Alcohol Withdrawal

Chronic alcohol use causes adaptive changes: GABA-A receptor downregulation and NMDA (glutamate) receptor upregulation. Abrupt cessation unmasks a state of CNS hyperexcitability. Noradrenergic hyperactivity (locus coeruleus disinhibition) drives autonomic symptoms. Kindling phenomenon: repeated withdrawal episodes become progressively more severe due to neuroplastic changes in excitatory circuits.

Timeline and Stages of Withdrawal

Minor Withdrawal (6-24 hours after last drink)

Tremor (the earliest and most common sign), anxiety, insomnia, diaphoresis, palpitations. Nausea, vomiting, anorexia. Intact sensorium (clear consciousness)

Alcoholic Hallucinosis (12-48 hours)

Visual, auditory, or tactile hallucinations with INTACT sensorium (patient knows the hallucinations are not real, or at least remains oriented) Distinct from delirium tremens (no clouding of consciousness) Usually resolves within 24-48 hours. May not progress to DT.

Withdrawal Seizures (12-48 hours, peak at 24 hours)

Generalized tonic-clonic seizures, typically brief and self-limiting. Occur in ~5-10% of patients with alcohol withdrawal. Usually single or in a brief cluster (2-3 seizures) Status epilepticus is uncommon but possible. Do NOT require long-term anticonvulsant therapy (they are withdrawal-related, not epileptic) Seizures are a risk factor for subsequent development of DT.

Delirium Tremens (48-96 hours; can be delayed up to 5-7 days)

The most severe and dangerous form of alcohol withdrawal. Features: delirium (fluctuating consciousness, disorientation, inattention), autonomic hyperactivity (tachycardia, hypertension, hyperthermia, diaphoresis), agitation, hallucinations (typically vivid visual), tremor. Occurs in ~5% of hospitalized alcohol withdrawal patients. Mortality: 1-5% with treatment; up to 35% untreated. Risk factors for DT: history of DT or withdrawal seizures, concurrent illness, older age, heavy prolonged use, elevated BAL at presentation, abnormal LFTs, low platelets, hypokalemia.

Assessment

CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol -- Revised)

10-item clinician-administered scale; scores range 0-67. Assesses: nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, orientation/clouding of sensorium.

Scoring interpretation:. < 10: mild withdrawal (may not require pharmacotherapy) 10-18: moderate withdrawal (consider treatment) > 18: severe withdrawal (treatment indicated) > 20: high risk for complications (seizures, DT) Requires a cooperative, communicative patient -- NOT valid in intubated, delirious, or obtunded patients. Administer every 1-4 hours depending on severity.

Limitations of CIWA-Ar

Cannot be used in patients who are unable to communicate (ICU patients, severe DT) Susceptible to symptom exaggeration (subjective items) May underestimate severity in patients on beta-blockers or clonidine (mask autonomic signs) Alternative: MINDS (Minnesota Detoxification Scale) for ICU patients.

Management

Symptom-Triggered Protocol

Benzodiazepines administered based on CIWA-Ar scores (e.g., give diazepam 10-20 mg or chlordiazepoxide 50-100 mg for CIWA >= 10; reassess hourly) Advantages over fixed-schedule dosing: shorter treatment duration, less total benzodiazepine used, lower risk of oversedation. Evidence: Saitz et al. (1994) demonstrated symptom-triggered was superior to fixed-schedule. Contraindication to symptom-triggered: patients unable to be assessed with CIWA (ICU, non-communicative); use fixed-schedule dosing in these patients.

Fixed-Schedule Protocol

Benzodiazepines given at regular intervals (e.g., chlordiazepoxide 50 mg q6h for day 1, taper over 4-5 days) with PRN supplementation for breakthrough symptoms. Appropriate for patients who cannot be monitored with CIWA, or in settings without nursing capacity for frequent reassessment. Higher total benzodiazepine dose and longer treatment compared to symptom-triggered.

Benzodiazepine Selection

Long-acting (preferred for most patients):. Diazepam: rapid onset, active metabolites provide self-tapering effect; preferred in many protocols; avoid in severe hepatic impairment. Chlordiazepoxide: long half-life, smoother withdrawal; less euphoria/abuse potential; commonly used in inpatient settings. Short-acting (preferred in hepatic impairment and elderly):. Lorazepam: no active metabolites, glucuronidation only (safe in liver disease); shorter half-life requires more frequent dosing. Oxazepam: similar advantages to lorazepam; less commonly used. "LOT" mnemonic: Lorazepam, Oxazepam, Temazepam -- the three benzodiazepines with no active metabolites, safe in liver disease (all undergo glucuronidation)

Front-Loading Protocol

Large doses of diazepam (10-20 mg IV every 5-15 minutes) administered until the patient is calm but awake. Utilizes diazepam's long half-life and active metabolites for a self-tapering effect. Reduces need for repeated dosing over subsequent days. Requires close monitoring (respiratory depression, oversedation)

Phenobarbital

Increasingly used as first-line or adjunctive agent for severe withdrawal. Advantages: GABA-A agonist at a different binding site than benzodiazepines; effective in benzodiazepine-refractory withdrawal; long half-life provides smooth tapering. Typical dosing: 130-260 mg IV as needed, or loading dose protocol (10 mg/kg over several hours) Can be used as monotherapy or combined with benzodiazepines. Risks: respiratory depression (especially combined with benzodiazepines), narrow therapeutic index, prolonged sedation. Recent trend toward phenobarbital-based protocols in the ICU for refractory cases.

Adjunctive Medications

Thiamine: 100-500 mg IV before glucose (to prevent Wernicke encephalopathy); continue 100 mg PO daily. Folate: 1 mg daily (chronic alcohol use depletes folate) Magnesium: replace if low (common in AUD; low Mg lowers seizure threshold) Electrolyte monitoring: potassium, phosphorus, magnesium frequently deranged. Clonidine: alpha-2 agonist; reduces autonomic symptoms (tachycardia, hypertension, diaphoresis) but does NOT prevent seizures or DT -- adjunctive only. Dexmedetomidine: alpha-2 agonist used as adjunct in ICU for refractory agitation; reduces benzodiazepine requirements; advantage of minimal respiratory depression. Valproic acid: some evidence as adjunctive anticonvulsant; not first-line. Carbamazepine: used as monotherapy for mild-moderate withdrawal in European protocols; not standard in the US.

ICU-Level Management of Delirium Tremens

Continuous benzodiazepine infusion (midazolam) or escalating boluses of diazepam/lorazepam. Add phenobarbital for benzodiazepine-refractory DT. Propofol infusion in extreme cases (intubated patients with refractory agitation) Dexmedetomidine infusion as adjunct to reduce benzodiazepine requirements. Continuous telemetry, frequent vitals, electrolyte monitoring q6-8h. Aggressive fluid resuscitation and electrolyte repletion. Avoid physical restraints when possible (increase hyperthermia and rhabdomyolysis risk) Anticipate complications: aspiration, rhabdomyolysis, arrhythmias, cardiovascular collapse.

Wernicke Encephalopathy -- Do Not Miss

Triad: encephalopathy (confusion), oculomotor dysfunction (nystagmus, ophthalmoplegia), gait ataxia -- full triad present in only ~10-16% of cases. Caused by thiamine (B1) deficiency. Treatment: HIGH-DOSE IV thiamine (200-500 mg TID for 3-5 days) before any glucose administration. If untreated, progresses to Korsakoff syndrome (irreversible anterograde amnesia, confabulation) Give thiamine empirically to ALL patients in alcohol withdrawal -- do not wait for symptoms.

<image> A timeline diagram showing the progression of alcohol withdrawal symptoms. Horizontal axis represents hours since last drink (0 to 120+ hours). Show overlapping bars for: minor withdrawal symptoms (6-24h), alcoholic hallucinosis (12-48h), withdrawal seizures (12-48h, peak 24h), and delirium tremens (48-96h, can extend to 7 days). For each phase, list key symptoms. Include a severity gradient from bottom to top. Mark the danger zone for DT with mortality data. Clinical education format. </image>

<image> A flowchart for alcohol withdrawal management. Start with "Patient at risk for alcohol withdrawal." Assess with CIWA-Ar. Branch by score: mild (< 10, supportive care, thiamine, monitor), moderate (10-18, symptom-triggered benzodiazepine protocol), severe (> 18, aggressive benzodiazepine dosing, consider front-loading or phenobarbital). If DT develops: ICU transfer, continuous benzodiazepine infusion, add phenobarbital, dexmedetomidine. Include a sidebar on CIWA limitations and when to use fixed-schedule instead. Color-coded algorithm. </image>

<image> A comparison table of benzodiazepine options for alcohol withdrawal. Columns for diazepam, chlordiazepoxide, and lorazepam. Rows: onset of action, half-life, active metabolites, hepatic safety, route of administration, typical protocol dosing, advantages, and disadvantages. Include a footer note about the LOT mnemonic (Lorazepam, Oxazepam, Temazepam -- safe in liver disease). Clinical reference format. </image>

Clinical Pearls

Symptom-triggered benzodiazepine dosing (guided by CIWA-Ar) is superior to fixed-schedule dosing in communicative patients -- it reduces total benzodiazepine use and treatment duration. CIWA-Ar is NOT valid in non-communicative, intubated, or delirious patients -- switch to fixed-schedule or phenobarbital-based protocols in the ICU. Give thiamine 200-500 mg IV BEFORE glucose in all alcohol withdrawal patients -- Wernicke encephalopathy is underdiagnosed and the consequences of missing it (Korsakoff syndrome) are irreversible. For liver disease patients, use lorazepam (no active metabolites, glucuronidation only) -- avoid diazepam and chlordiazepoxide. Withdrawal seizures do NOT require long-term anticonvulsant therapy -- they are self-limited and best prevented with adequate benzodiazepine dosing. The kindling phenomenon means each successive withdrawal episode tends to be more severe -- this underscores the importance of treating early and connecting patients with AUD treatment before the next cycle. Phenobarbital is making a comeback for severe and benzodiazepine-refractory withdrawal -- know the dosing and monitoring requirements.

References

• Saitz R, et al. Individualized treatment for alcohol withdrawal: a randomized double-blind controlled trial. JAMA. 1994;272(7):519-523.
• Sullivan JT, et al. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353-1357.
• Hack JB, et al. Phenobarbital for alcohol withdrawal: a systematic review and meta-analysis. J Med Toxicol. 2023;19(2):171-181.
• Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109-2113.
• ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020;14(3S):1-72.

Read this lecture as Markdown